This trial is evaluating whether ixazomib will improve 2 primary outcomes and 12 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Up to 4 weeks post study treatment.
This trial requires 117 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ixazomib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The overall risk of developing multiple myeloma depends on the risk of developing one individual cancer type independently. The probability of developing multiple myeloma is greater when a person develops one of the solid tumor cancers. Those with solid tumors have an increased risk of developing multiple myeloma over the following 15 years, compared with people with only non-solid tumors." - Anonymous Online Contributor
"There is no evidence that ixazomib, as currently used, has major drug interactions. However, there are no studies of ixazomib as a monotherapy, except for those in post-hx rels. There is little data available regarding the safety and efficacy of ixazomib in combination, but a recent Phase III study on relapsed and refractory multiple myeloma found a higher than expected response rate in patients with refractory to bortezomib-based regimens with a minimum PFS of 7.5 months, which is in the same range as those reported with ixazomib." - Anonymous Online Contributor
"There are important prognostic factors for prognosis of [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) patients. Survival rate appears to correlate with disease stage and occurrence of extramedullary myeloma. Survival rates can be predicted with the use of multivariate Cox model including parameters which can be obtained before initiation of treatment or before the occurrence of myeloma." - Anonymous Online Contributor
"Almost 9 in 10 MM cases will be treated with one of the various agents or combinations of agents currently available and use in MM. In addition, MM represents about a quarter of all hematologic malignancies (excluding leukemia) seen by oncology providers in the U.S. A single institution in New Haven County, Connecticut, treated 9,832 MM patients in a 2-year period between 1988 and 1990 and documented that at this facility and in a large number of other hospitals, 8,050 MM patients were treated between 1980 and 1983. Based on these reported data, multiple myeloma is expected to be responsible for about 4.8% of all hematological malignancies in the U.S." - Anonymous Online Contributor
"Effective treatment with corticosteroids, immunotherapy, or, especially, combination therapy, is associated with a 50% or higher chance of five-year overall survival in patients with multiple myeloma. A prospective, multicenter study with standardized follow-up is needed to establish cure of multiple myeloma." - Anonymous Online Contributor
"There is some evidence of both genetic and environmental involvement in multiple myeloma, but these explanations do not fully account for the observed associations. There is further evidence for a role of viruses in the carcinogenesis of multiple myeloma and for viral infection in the development of multiple myeloma, with links possibly between multiple myeloma and human T-lymphotropic virus 1." - Anonymous Online Contributor
"Most patients with MM experience loss of appetite and weight loss and they often have fatigue. Patients with multiple myeloma may have low self-esteem, which is evident when they discuss their symptoms because they may be viewed as a debilitating disease by their friends or family members." - Anonymous Online Contributor
"Patients diagnosed with MM may have difficulty navigating the health care system, and experience high levels of distress and quality of life impairment. Findings from a recent study suggest early initiation of adjunctive services for treatment of cancer symptom distress to maintain psychological, physical, social, and spiritual well being." - Anonymous Online Contributor
"Due to variations in health insurance systems, medical coverage, and treatment in each country, this list is only indicative, and not exhaustive, of the most common treatments for common MM variants. While some treatments are less common in some places, some treatments are more often administered in the developed world, where they are often more effective. In all likelihood, the vast majority of patients with MM received standard therapies before the discovery and development of newer treatments. These treatments often are effective at arresting or slowing progression of disease and improving symptoms, but they do not cure multiple myeloma. While treatments are improving, they are still necessary because MM is a rapidly progressing disease, and most patients relapse within 5 years of treatment." - Anonymous Online Contributor
"In this large and nationwide sample, patients treated between 1990s and early 2000s accounted for about 50% of all MM patients. Male and older patients were associated with shorter survival, as were young patient without a partner and with multiple myelomatous syndromes." - Anonymous Online Contributor
"Ixazomib proved to be more effective than a placebo for the treatment of relapsed and refractory patients with multiple myeloma. In a recent study, findings suggest ixazomib could be a standard treatment option for this indication." - Anonymous Online Contributor
"The overall results illustrate the complexity of both genetic factors and environmental factors in multiple myeloma. The clinical manifestations of multiple myeloma are the results of a complex interplay between somatic mutation, environmental risk factors, and the immunologic response to neoplastic cells." - Anonymous Online Contributor